A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide

Inclusion Criteria: * Study Subjects must be adults with confirmed or suspected Renal Artery stenosis. * The subject must have been referred for Digital Subtraction Angiography. Exclusion Criteria: * The subject has a known hypersensitivity to either conventional X-ray or gadolinium-based MR contrast media including, but not restricted to, the investigational product. * The subject is lactating. * The subject is pregnant as defined by a serum or urine β-HCG pregnancy test obtained within 24 hours before investigational product administration. * The subject has received or is scheduled to receive MRI contrast medium within 24 h prior to or less than 24 hours after the investigational product administration. * The subject has received or is scheduled to receive X-ray contrast medium within 7 days prior to or less than 24 hours after administration of investigational product. * The subject has received an investigational product within 30 days prior to or will receive an investigational product less than 24 hours after investigational product administration. * The subject has an active, serious, life-threatening disease with a life expectancy of less than 6 months. * The subject has had a percutaneous transluminal angioplasty (PTA) in the renal region performed within 4 weeks prior to investigational product administration. * The subject has a stent in the renal arteries. * The subject has had a kidney transplantation. * The subject has a serum creatinine value of \>3.5 mg/dL (309.4 µmol/L). * The subject has previously been included in this study. * The subject has a contra-indication for MRI according to accepted clinical guidelines.